ProQR Therapeutics N.V. (PRQR)
NASDAQ: PRQR · IEX Real-Time Price · USD
2.070
+0.070 (3.50%)
Apr 23, 2024, 1:44 PM EDT - Market open
ProQR Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ProQR Therapeutics stock have an average target of 4.00, with a low estimate of 2.00 and a high estimate of 6.00. The average target predicts an increase of 93.24% from the current stock price of 2.07.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for PRQR stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $1.8 → $2 | Hold | Maintains | $1.8 → $2 | -3.38% | Apr 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +141.55% | Mar 14, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $2 → $2.5 | Strong Buy | Maintains | $2 → $2.5 | +20.77% | Mar 14, 2024 |
| Raymond James | Raymond James | Buy Maintains $5 → $4 | Buy | Maintains | $5 → $4 | +93.24% | Nov 8, 2023 |
| Chardan Capital | Chardan Capital | Hold → Strong Buy Upgrades $2 | Hold → Strong Buy | Upgrades | $2 | -3.38% | Nov 8, 2023 |
Financial Forecast
Revenue This Year
14.84M
from 9.53M
Increased by 55.81%
Revenue Next Year
23.89M
from 14.84M
Increased by 60.95%
EPS This Year
-0.42
from -0.35
EPS Next Year
-0.47
from -0.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 28.8M | 44.5M | 21.0M | 14.4M | 106.9M |
| Avg | 14.8M | 23.9M | 15.2M | 7.2M | 37.5M |
| Low | n/a | 7.7M | 8.9M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 202.0% | 199.9% | -12.1% | -4.9% | 1,390.9% |
| Avg | 55.8% | 60.9% | -36.4% | -52.8% | 422.9% |
| Low | - | -48.1% | -62.9% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -0.30 | -0.28 | -0.39 |
| Avg | -0.42 | -0.47 | -0.54 |
| Low | -0.65 | -0.70 | -0.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.